Evolent Health, Inc Class A Common Stock (NY:EVH)

4.580 +0.040 (+0.88%)

Official Closing Price Updated: 7:00 PM EST, Nov 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Evolent Health, Inc Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

What Evolent Health (EVH) Said on Its Q3 Earnings Call ↗

November 07, 2026

Via MarketBeat

EVH Q3 2026 deep dive: ongoing AI investment and customer expansion shape outlook

November 06, 2026

Healthcare solutions company Evolent Health (NYSE:EVH) met Wall Street’s revenue expectations in Q3 2026, with sales up 51.3% year on year to $725.4 million....

Via StockStory

Topics Artificial Intelligence

Evolent Health (EVH) Q3 2026 Earnings Call Transcript ↗

November 05, 2026

Oncology and AI-driven efficiencies anchor the quarter's stronger profit picture.

Via The Motley Fool

Topics Artificial Intelligence Earnings

Evolent Health (NYSE:EVH) Q3 2026 Earnings: In-Line Revenue, EPS Beat, but Premarket Shares Slide ↗

November 05, 2026

Via Chartmill

Evolent Health (NYSE:EVH) Jumps 18% After Q2 Revenue and EPS Smash Estimates ↗

August 06, 2026

Via Chartmill

GoodRx, Evolent Health, UFP Technologies, Centene, and HCA Healthcare shares skyrocket, what you need to know

November 04, 2026

What happened? A number of stocks jumped in the afternoon session after election results confirmed that Democrats reclaimed majorities in the House and Senat...

Via StockStory

Evolent Health earnings: what to look for from EVH

November 03, 2026

Healthcare solutions company Evolent Health (NYSE:EVH) will be announcing earnings results this Thursday before the bell. Here’s what investors should know. ...

Via StockStory

1 surging stock with competitive advantages and 2 that underwhelm

October 29, 2026

Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a ne...

Via StockStory

1 unprofitable stock for long-term investors and 2 we avoid

October 26, 2026

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv...

Via StockStory

3 Value Stocks with Warning Signs

October 21, 2026

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the...

Via StockStory

1 Cash-Producing Stock to Target This Week and 2 Facing Headwinds

October 13, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Cas...

Via StockStory

Healthcare Technology for Providers Stocks Q2 Recap: Benchmarking Omnicell (NASDAQ:OMCL)

October 04, 2026

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking a...

Via StockStory

Healthcare Technology for Providers Stocks Q2 In Review: Astrana Health (NASDAQ:ASTH) Vs Peers

September 29, 2026

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the healthcare technology for providers stocks, including Astrana Health (NASDAQ:ASTH) ...

Via StockStory

Q2 Earnings Highlights: Tandem Diabetes (NASDAQ:TNDM) Vs The Rest Of The Healthcare Technology Stocks

September 29, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

3 Reasons to Avoid EVH and 1 Stock to Buy Instead

September 21, 2026

The past six months have been a windfall for Evolent Health’s shareholders. The company’s stock price has jumped 48.6%, hitting $3.70 per share. This was par...

Via StockStory

Topics Bankruptcy

Q2 Healthcare Technology for Providers Earnings: Evolent Health (NYSE:EVH) Impresses

September 15, 2026

Looking back on healthcare technology for providers stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Evolent Health (NYSE:...

Via StockStory

1 of Wall Street’s Favorite Stocks for Long-Term Investors and 2 We Find Risky

September 11, 2026

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...

Via StockStory

Healthcare Technology for Providers Stocks Q2 Teardown: Privia Health (NASDAQ:PRVA) Vs The Rest

September 09, 2026

Looking back on healthcare technology for providers stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Privia Health (NASDAQ...

Via StockStory

1 Value Stock with Promising Prospects and 2 That Underwhelm

September 01, 2026

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...

Via StockStory

Evolent Health (EVH) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Highmark launch drove 47% revenue growth; AI platform reached meaningful scale.

Via The Motley Fool

Topics Artificial Intelligence Earnings

5 Must-Read Analyst Questions From Evolent Health’s Q2 Earnings Call

August 13, 2026

Evolent Health’s second quarter results drew a significant positive market reaction, reflecting outperformance versus Wall Street’s expectations on both reve...

Via StockStory

Topics Earnings

1 Healthcare Stock Worth Your Attention and 2 We Brush Off

August 13, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have be...

Via StockStory

Reflecting On Healthcare Technology Stocks’ Q2 Earnings: GoodRx (NASDAQ:GDRX)

August 11, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at GoodRx (NASDAQ:GDRX) and its ...

Via StockStory

3 Stocks Under $10 with Questionable Fundamentals

August 10, 2026

Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying busi...

Via StockStory

Topics Artificial Intelligence

Evolent Health Q2 Earnings Call Highlights ↗

August 08, 2026

Evolent Health (NYSE:EVH) reported second-quarter revenue of $653 million, up 31% from the first quarter, and adjusted EBITDA of $28 million, up 27% sequentially, as the company benefited from the May...

Via MarketBeat

Topics Earnings

EVH Q2 2026 Deep Dive: Oncology Suite and AI Automation Drive Growth Amid Membership Headwinds

August 07, 2026

Healthcare solutions company Evolent Health (NYSE:EVH) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 46.9% year on yea...

Via StockStory

Topics Artificial Intelligence

Evolent Health (NYSE:EVH) Reports Bullish Q2 CY2026, Stock Jumps 18.2%

August 06, 2026

Healthcare solutions company Evolent Health (NYSE:EVH) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 46.9% year on yea...

Via StockStory

Evolent Health Earnings: What To Look For From EVH

August 04, 2026

Healthcare solutions company Evolent Health (NYSE:EVH) will be reporting earnings this Thursday before market hours. Here’s what to look for. Evolent Health ...

Via StockStory

1 Small-Cap Stock for Long-Term Investors and 2 We Brush Off

July 31, 2026

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...

Via StockStory

Why Evolent Health (EVH) Stock Is Nosediving

July 23, 2026

What Happened? Shares of healthcare solutions company Evolent Health (NYSE:EVH) fell 13% in the afternoon session after Wall Street firm Citi downgraded the ...

Via StockStory

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.